Sign up to save your podcasts
Or
Share Peanut Allergies Return Unless Therapy Continues
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Peanut Allergies Return Unless Therapy Continues
Vidcast: https://youtu.be/OSjfU5mXNbI
Studies prove that oral exposure to peanut protein can tame deadly peanut allergies. The FDA just approved a drug therapy program, Palforzia, to do just that.
A Stanford University study now shows that peanut reactivity will return unless therapeutic peanut exposures continue. The researchers studied 120 peanut-allergic participants.
After nearly 3.5 months of ever increasing peanut protein, all were successfully desensitized and could safely consume the equivalent of 200 peanuts. Stopping the 200 peanut treatments completely or continuing with daily exposures of only 15 peanuts a day failed to maintain peanut non-reactivity.
This result suggests that any desensitization program, including Palforzia, will require continuation of therapy for an extended period. It would be dangerous to stop.
R Sharon Chinthrajah, MD ,Natasha Purington, MS, Sandra Andorf, PhD, etal. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. Published:September 12, 2019DOI:https://doi.org/10.1016/S0140-6736(19)31793-3
#Peanutallergy #oralimmmunotherapy
View all episodes
By Howard G. Smith MD, AMVidcast: https://youtu.be/OSjfU5mXNbI
Studies prove that oral exposure to peanut protein can tame deadly peanut allergies. The FDA just approved a drug therapy program, Palforzia, to do just that.
A Stanford University study now shows that peanut reactivity will return unless therapeutic peanut exposures continue. The researchers studied 120 peanut-allergic participants.
After nearly 3.5 months of ever increasing peanut protein, all were successfully desensitized and could safely consume the equivalent of 200 peanuts. Stopping the 200 peanut treatments completely or continuing with daily exposures of only 15 peanuts a day failed to maintain peanut non-reactivity.
This result suggests that any desensitization program, including Palforzia, will require continuation of therapy for an extended period. It would be dangerous to stop.
R Sharon Chinthrajah, MD ,Natasha Purington, MS, Sandra Andorf, PhD, etal. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. Published:September 12, 2019DOI:https://doi.org/10.1016/S0140-6736(19)31793-3
#Peanutallergy #oralimmmunotherapy